Drug Trial Radar · NCT03682068
Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer
Last checked: Nov 20, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,246
Actual
Start
Sep 27, 2018
Primary completion
Jun 1, 2026
Study completion Jun 1, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Sep 24, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, open-label, controlled, multi-center, global Phase III study to determine the efficacy and safety of combining durvalumab ± tremelimumab with standard of care (SoC) chemotherapy (cisplatin + gemcitabine or carboplatin + gemcitabine doublet) followed by durvalumab monotherapy versus SoC alone as first-line chemotherapy in patients with histologically or cytologically documented, unresectable, locally advanced or metastatic transitional cell carcinoma of the urothelium (including renal pelvis, ureters, urinary bladder, and urethra).
Conditions
- Unresectable Locally Advanced Urothelial Cancer
- Metastatic Urothelial Cancer
Interventions
DurvalumabDrug
Durvalumab IV (intravenous infusion)
TremelimumabDrug
Tremelimumab IV (intravenous infusion)
Cisplatin + GemcitabineDrug
Cisplatin IV (intravenous)+ Gemcitabine IV(intravenous), as standard of care.
Carboplatin + GemcitabineDrug
Carboplatin IV (intravenous)+ Gemcitabine IV(intravenous), as standard of care.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: approximately 5 years
Locations
222 sites in 22 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Bakersfield, California
Research Site
Fullerton, California
Research Site
Los Angeles, California
Research Site
Salinas, California
Research Site
Santa Barbara, California
Research Site
Truckee, California
Research Site
New Haven, Connecticut
Research Site
Washington D.C., District of Columbia
Research Site
Orlando, Florida
Research Site
Chicago, Illinois
Research Site
Fort Wayne, Indiana
Research Site
Kansas City, Kansas
Research Site
Louisville, Kentucky
Research Site
New Orleans, Louisiana
Research Site
Grand Rapids, Michigan
Research Site
Bozeman, Montana
Research Site
New Hyde Park, New York
Research Site
New York, New York
Research Site
New York, New York
Research Site
Rochester, New York
Research Site
Germantown, Tennessee
Research Site
Fort Worth, Texas
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
Rosario, Argentina
Research Site
Box Hill, Australia
Research Site
Elizabeth Vale, Australia
Research Site
Kogarah, Australia
Research Site
Macquarie University, Australia
Research Site
Murdoch, Australia
Research Site
Orange, Australia
Research Site
South Brisbane, Australia
Research Site
St Albans, Australia
Research Site
Curitiba, Brazil
Research Site
Fortaleza, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Porto Alegre, Brazil
Showing 40 of 222 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.